Adam Abeshouse dies at 63 from Bile Duct Cancer

Adam Abeshouse's clients joined him at the studio adjacent to his home for a farewell concert. Joshua Bell, first row, from left, Adam Abeshouse, Larisa Martinez and Kevin Puts. And, second row, from left, John-Henry Crawford, Charles Yang, Peter Dugan, Lara Downes, Ranaan Meyer, Garrick Ohlsson, Jeremy Denk, Nicolas Kendall and Simone Dinnerstein. NPR.

Early in 2024, Adam Abeshouse was diagnosed with bile duct cancer, and the disease swiftly metastasized. He was a producer who inspired great love and loyalty with the artists he worked with. Shortly before the end of his life, a dozen of his celebrity clients came together to perform for Abeshouse one last time, in a private concert at his home studio.

"In 2002, Adam Abeshouse founded the Classical Recording Foundation to help artists record music they were passionate about but might not have economic appeal. Because he said, “Recordings are just as important an art form as live performance."

A force that will be missed, but a strong legacy that lives on. RIP, Adam Abeshouse.

Cholangiocarcinoma Foundation Webinar

 

Mark Yarchoan, MD
Johns Hopkins University

This webinar will introduce an upcoming clinical trial at Johns Hopkins, led by Drs. Marina Baretti, Nilo Azad, and Mark Yarchoan.

The trial focuses on a therapeutic vaccine designed to boost the effectiveness of standard immunotherapy drugs for cholangiocarcinoma. Dr. Yarchoan will present information about the vaccine and provide a broader overview of how therapeutic cancer vaccines have evolved.

The discussion will cover past challenges, recent breakthroughs (including successes with vaccines in other types of cancer), and how these advancements could shape future cancer treatments.

Thursday, October 10, 2024

4:00pm (EDT)

Register now.

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

FDA

"Previously, certepetide was granted ODD by the FDA for use as a potential therapeutic option in patients with malignant glioma in August 2023; rare pediatric disease designation in osteosarcoma in March, 2024; and ODD for osteosarcoma in April 2024. Additionally, the agent received orphan drug designation for pancreatic cancer by the European Medicines Agency’s Committee for Orphan Medical Products in October 2023, and fast track designation from the FDA in this disease setting.

"Patients in the first-line cohort will receive 1500 mg of intravenous (IV) durvalumab every 21 days plus 25 mg/m² of IV cisplatin and 1000 mg/m² of IV gemcitabine on day 1 and 8 every 21 days for 8 cycles, then every 28 days for additional cycles. In the second-line cohort, patients will receive FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) every 14 days. These respective regimens will be administered alongside either placebo or 3.2 mg/kg of IV certepetide as a slow push over 1 minute. The study’s primary end point is the incidence of adverse effects."

Check the article to learn more about this ODD, including citations and footnotes.

Cholangiocarcinoma Foundation September Support Groups

The Cholangiocarcinoma Foundation is offering virtual support groups (ZOOM) for September 2024. These support groups allow people who have been impacted by the disease to share personal experiences and learn from others. Participants must register to attend the virtual sessions that may include special guest moderators.

• Sept. 5 - Patient Support Group 
• Sept. 9 - Bereaved Support Group 
• Sept. 11 - Spanish Support Group 
• Sept. 16 - Patient Support Group 
• Sept. 18 - Canadian Support Group 
• Sept. 19 - Caregiver Support Group 
• Sept. 25 - French Canadian Support Group 

Click Here for more information about the Virtual Support Groups. 

Additional opportunities to connect with the CCF community include:

• CholangioConnect, which partners patients and caregivers with mentors to provide additional support.  (Learn More) 
• Cholangiocarcinoma 101 Video Series and links to other resources for patients and caregivers.